207 related articles for article (PubMed ID: 10671909)
1. Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population.
Ou-Yang DS; Huang SL; Wang W; Xie HG; Xu ZH; Shu Y; Zhou HH
Br J Clin Pharmacol; 2000 Feb; 49(2):145-51. PubMed ID: 10671909
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations.
Fuhr U; Rost KL; Engelhardt R; Sachs M; Liermann D; Belloc C; Beaune P; Janezic S; Grant D; Meyer UA; Staib AH
Pharmacogenetics; 1996 Apr; 6(2):159-76. PubMed ID: 9156694
[TBL] [Abstract][Full Text] [Related]
3. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva.
Fuhr U; Rost KL
Pharmacogenetics; 1994 Jun; 4(3):109-16. PubMed ID: 7920690
[TBL] [Abstract][Full Text] [Related]
4. Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans.
Rasmussen BB; Brøsen K
Br J Clin Pharmacol; 1997 Mar; 43(3):253-8. PubMed ID: 9088579
[TBL] [Abstract][Full Text] [Related]
5. The G-113A polymorphism in CYP1A2 affects the caffeine metabolic ratio in a Chinese population.
Chen X; Wang L; Zhi L; Zhou G; Wang H; Zhang X; Hao B; Zhu Y; Cheng Z; He F
Clin Pharmacol Ther; 2005 Sep; 78(3):249-59. PubMed ID: 16153396
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic polymorphism of CYP2A6 activity in a Chinese population.
Xu P; Huang SL; Zhu RH; Han XM; Zhou HH
Eur J Clin Pharmacol; 2002 Aug; 58(5):333-7. PubMed ID: 12185557
[TBL] [Abstract][Full Text] [Related]
7. Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population.
Gunes A; Ozbey G; Vural EH; Uluoglu C; Scordo MG; Zengil H; Dahl ML
Pharmacogenomics; 2009 May; 10(5):769-78. PubMed ID: 19450128
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics.
Perera V; Gross AS; Xu H; McLachlan AJ
J Pharm Pharmacol; 2011 Sep; 63(9):1161-8. PubMed ID: 21827488
[TBL] [Abstract][Full Text] [Related]
9. Paraxanthine/Caffeine Concentration Ratios in Hair: An Alternative for Plasma-Based Phenotyping of Cytochrome P450 1A2?
De Kesel PM; Lambert WE; Stove CP
Clin Pharmacokinet; 2015 Jul; 54(7):771-81. PubMed ID: 25603821
[TBL] [Abstract][Full Text] [Related]
10. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene.
Nakajima M; Yokoi T; Mizutani M; Shin S; Kadlubar FF; Kamataki T
Cancer Epidemiol Biomarkers Prev; 1994; 3(5):413-21. PubMed ID: 7920209
[TBL] [Abstract][Full Text] [Related]
11. Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma.
Perera V; Gross AS; McLachlan AJ
Biomed Chromatogr; 2010 Oct; 24(10):1136-44. PubMed ID: 20853468
[TBL] [Abstract][Full Text] [Related]
12. Association between common CYP1A2 polymorphisms and theophylline metabolism in non-smoking healthy volunteers.
Wang L; Hu Z; Deng X; Wang Y; Zhang Z; Cheng ZN
Basic Clin Pharmacol Toxicol; 2013 Apr; 112(4):257-63. PubMed ID: 23167834
[TBL] [Abstract][Full Text] [Related]
13. Validation of a high-performance liquid chromatography assay for quantification of caffeine and paraxanthine in human serum in the context of CYP1A2 phenotyping.
Koch JP; ten Tusscher GW; Koppe JG; Guchelaar HJ
Biomed Chromatogr; 1999 Jun; 13(4):309-14. PubMed ID: 10416066
[TBL] [Abstract][Full Text] [Related]
14. Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment.
Rostami-Hodjegan A; Nurminen S; Jackson PR; Tucker GT
Pharmacogenetics; 1996 Apr; 6(2):121-49. PubMed ID: 9156692
[TBL] [Abstract][Full Text] [Related]
15. Paraxanthine/caffeine ratio: as an index for CYP1A2 activity in polycyclic aromatic hydrocarbons exposed subjects.
Wittayalertpanya S; Hinsui Y; Lawanprasert S
J Med Assoc Thai; 2003 Jun; 86 Suppl 2():S310-7. PubMed ID: 12930004
[TBL] [Abstract][Full Text] [Related]
16. Nonparametric expectation maximisation (NPEM) population pharmacokinetic analysis of caffeine disposition from sparse data in adult caucasians: systemic caffeine clearance as a biomarker for cytochrome P450 1A2 activity.
Terziivanov D; Bozhinova K; Dimitrova V; Atanasova I
Clin Pharmacokinet; 2003; 42(15):1393-409. PubMed ID: 14674790
[TBL] [Abstract][Full Text] [Related]
17. Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping.
Kashuba AD; Bertino JS; Kearns GL; Leeder JS; James AW; Gotschall R; Nafziger AN
Clin Pharmacol Ther; 1998 May; 63(5):540-51. PubMed ID: 9630827
[TBL] [Abstract][Full Text] [Related]
18. Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans.
Bapiro TE; Sayi J; Hasler JA; Jande M; Rimoy G; Masselle A; Masimirembwa CM
Eur J Clin Pharmacol; 2005 Nov; 61(10):755-61. PubMed ID: 16261361
[TBL] [Abstract][Full Text] [Related]
19. Two novel methods for the determination of CYP1A2 activity using the paraxanthine/caffeine ratio.
Doude van Troostwijk LJ; Koopmans RP; Guchelaar HJ
Fundam Clin Pharmacol; 2003 Jun; 17(3):355-62. PubMed ID: 12803575
[TBL] [Abstract][Full Text] [Related]
20. Variation of CYP1A2-dependent caffeine metabolism during menstrual cycle in healthy women.
Zaigler M; Rietbrock S; Szymanski J; Dericks-Tan JS; Staib AH; Fuhr U
Int J Clin Pharmacol Ther; 2000 May; 38(5):235-44. PubMed ID: 10839467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
